样式: 排序: IF: - GO 导出 标记为已读
-
Developing effective strategies to optimize physical activity and cardiorespiratory fitness in the long Covid population- The need for caution and objective assessment Prog. Cardiovasc. Dis. (IF 9.1) Pub Date : 2024-03-08 Mark A. Faghy, Rae Duncan, Emily Hume, Lewis Gough, Clare Roscoe, Deepika Laddu, Ross Arena, Ruth E.M. Asthon, Caroline Dalton
The Post Covid-19 Condition (commonly known as Long Covid) has been defined by the World Health Organisation as occurring in individuals with a history of probable or confirmed SARS CoV 2 infection, usually within 3 months from the onset of acute Covid-19 infection with symptoms that last for at least two months which cannot be explained by an alternative diagnosis. Long Covid is associated with over
-
Artificial intelligence in preventive cardiology Prog. Cardiovasc. Dis. (IF 9.1) Pub Date : 2024-03-07 Adham El Sherbini, Robert S. Rosenson, Mahmoud Al Rifai, Hafeez Ul Hassan Virk, Zhen Wang, Salim Virani, Benjamin S. Glicksberg, Carl J. Lavie, Chayakrit Krittanawong
Artificial intelligence (AI) is a field of study that strives to replicate aspects of human intelligence into machines. Preventive cardiology, a subspeciality of cardiovascular (CV) medicine, aims to target and mitigate known risk factors for CV disease (CVD). AI's integration into preventive cardiology may introduce novel treatment interventions and AI-centered clinician assistive tools to reduce
-
Qualitative systems mapping in promoting physical activity and cardiorespiratory fitness: Perspectives and recommendations Prog. Cardiovasc. Dis. (IF 9.1) Pub Date : 2024-02-29 Nicolaas P. Pronk, Bruce Y. Lee
The purpose of this report is to provide a perspective on the use of qualitative systems mapping, provide examples of physical activity (PA) systems maps, discuss the role of PA systems mapping in the context of iterative learning to derive breakthrough interventions, and provide actionable recommendations for future work. Systems mapping methods and applications for PA are emerging in the scientific
-
Cardiorespiratory fitness and physical activity in the lens of social justice – Reporting on the disparities that exist Prog. Cardiovasc. Dis. (IF 9.1) Pub Date : 2024-02-28 Zach Cooper, Wendy Avila Rodriguez, Joel Hardwick, Ross Arena, Deepika R. Laddu
Cardiorespiratory fitness (CRF), heavily influenced by physical activity (PA), represents a strong and independent risk factor for a wide range of health conditions, most notably, cardiovascular disease. Substantial disparities in CRF have been identified between white and non-white populations. These disparities may partly account for group differences in susceptibility to poor health outcomes, including
-
How to interpret a cardiorespiratory fitness assessment – Key measures that provide the best picture of health, disease status and prognosis Prog. Cardiovasc. Dis. (IF 9.1) Pub Date : 2024-02-28 Cemal Ozemek, Joel Hardwick, Amanda Bonikowske, Jeffrey Christle, Charles German, Satyajit Reddy, Ross Arena, Mark Faghy
Graded exercise testing is a widely accepted tool for revealing cardiac ischemia and/or arrhythmias in clinical settings. Cardiopulmonary exercise testing (CPET) measures expired gases during a graded exercise test making it a versatile tool that helps reveal underlying physiologic abnormalities that are in many cases only present with exertion. It also characterizes one's health status and clinical
-
Global status of cardiorespiratory fitness and physical activity – Are we improving or getting worse? Prog. Cardiovasc. Dis. (IF 9.1) Pub Date : 2024-02-27 Andrew P. Hills, Sisitha Jayasinghe, Ross Arena, Nuala M. Byrne
Despite heightened recognition of the importance of cardiorespiratory fitness (CRF) to cardiovascular (CV) health, along with updated international consensus guidelines for physical activity (PA) and sedentary behavior (SB), significant proportions of the global adult population are physically inactive, and do not meet the threshold for CRF. Physical inactivity is considered a surrogate for low CRF
-
Trends in the association between meeting the physical activity guidelines and risk of mortality in US adults Prog. Cardiovasc. Dis. (IF 9.1) Pub Date : 2024-02-27 David Martinez-Gomez, Fernando Rodriguez-Artalejo, Ding Ding, Ulf Ekelund, Veronica Cabanas-Sanchez
To examine the trends in the association between meeting the physical activity (PA) guidelines and mortality in adults. We included seventeen annual representative samples of US adults 1998–2014 ( = 482,756) and all-cause and cause-specific mortality ascertained through December 2019. Participants were grouped according to PA Guidelines: 150 or more min/week in aerobic PA and muscle-strengthening activities
-
Assessing cardiorespiratory fitness in clinical and community settings: Lessons and advancements in the 100th year anniversary of VO2max Prog. Cardiovasc. Dis. (IF 9.1) Pub Date : 2024-02-27 Matthew P. Harber, Jonathan Myers, Amanda R. Bonikowske, Adria Muntaner-Mas, Pablo Molina-Garcia, Ross Arena, Francisco B. Ortega
Cardiorespiratory fitness (CRF) is a well-established biomarker that has applications to all adults across the health and disease spectrum. Despite overwhelming evidence supporting the prognostic utility of CRF, it remains vastly underutilized. CRF is optimally measured via cardiopulmonary exercise testing which may not be feasible to implement on a large scale. Therefore, it is prudent to develop
-
Testosterone therapy and the risk of cardiovascular disease in older, hypogonadal men Prog. Cardiovasc. Dis. (IF 9.1) Pub Date : 2024-02-27 Srikanth Krishnan, Jairo Aldana-Bitar, Ilana Golub, Keishi Ichikawa, Ayesha Shabir, Marziyeh Bagheri, Hossein Hamidi, Travis Benzing, Sina Kianoush, Matthew J. Budoff
The debate over the cardiovascular (CV) implications of testosterone therapy (TT) have resulted in diverging safety recommendations and clinical guidelines worldwide. This narrative review synthesizes and critically evaluates long-term studies examining the effects of TT within the context of aging, obesity, and endogenous sex hormones on CV disease (CVD) risk to support informed clinical decision-making
-
Evidence to support health system prioritization of health behaviors in the COVID-19 era Prog. Cardiovasc. Dis. (IF 9.1) Pub Date : 2024-02-27 Meghan M. JaKa, Jeanette Y. Ziegenfuss, Jennifer M. Dinh, Laura J. Jacobson, Thomas E. Kottke, Susan M. Knudson, Chad C. Heim, Jason M. Gallagher, Kevin D. Campbell, Rachael L. Rivard, Nicolaas P. Pronk
Since the COVID-19 pandemic health systems have shifted necessarily from chronic to infectious disease treatment, but chronic disease remains critical. One large health system uniquely tracks member health behaviors. This analysis compares data from select months of an ongoing monthly cross-sectional survey before and during the pandemic. Responses in April 2019 (pre-pandemic), April 2020 (early pandemic)
-
Using cardiorespiratory fitness assessment to identify pathophysiology in long COVID – Best practice approaches Prog. Cardiovasc. Dis. (IF 9.1) Pub Date : 2024-02-27 Mark A. Faghy, Caroline Dalton, Rae Duncan, Ross Arena, Ruth E.M. Ashton
Cardio-respiratory fitness (CRF) is well-established in the clinical domains as an integrative measure of the body's physiological capability and capacity to transport and utilise oxygen during controlled bouts of physical exertion. Long COVID is associated with >200 different symptoms and is estimated to affect ∼150 million people worldwide. The most widely reported impact is reduced quality of life
-
The physiologic benefits of optimizing cardiorespiratory fitness and physical activity – From the cell to systems level in a post-pandemic world Prog. Cardiovasc. Dis. (IF 9.1) Pub Date : 2024-02-27 Mark A. Faghy, Amanda Tatler, Corinna Chidley, Simon Fryer, Lee Stoner, Deepika Laddu, Ross Arena, Ruth E. Ashton
Cardiovascular (CV) disease (CVD) is a leading cause of premature death and hospitalization which places a significant strain on health services and economies around the World. Evidence from decades of empirical and observational research demonstrates clear associations between physical activity (PA) and cardiorespiratory fitness (CRF) which can offset the risk of mortality and increase life expectancy
-
Exercise-based cardio-oncology rehabilitation for cardiotoxicity prevention during breast cancer chemotherapy: The ONCORE randomized controlled trial Prog. Cardiovasc. Dis. (IF 9.1) Pub Date : 2024-02-21 Estíbaliz Díaz-Balboa, Carlos Peña-Gil, Beatriz Rodríguez-Romero, Antonio I. Cuesta-Vargas, Oscar Lado-Baleato, Amparo Martínez-Monzonís, Milagros Pedreira-Pérez, Patricia Palacios-Ozores, Rafael López-López, José R. González-Juanatey, Violeta González-Salvado
Breast cancer (BC) treatment with anthracyclines and/or anti-human epidermal growth factor receptor-2 (HER2) antibodies is associated with an increased risk of cardiovascular disease complications, including cancer therapy-related cardiac dysfunction (CTRCD). While Cardio-Oncology Rehabilitation (CORe) programs including exercise have emerged to minimize these risks, its role in preventing CTRCD is
-
Update to the 2016 American Heart Association cardiorespiratory fitness statement Prog. Cardiovasc. Dis. (IF 9.1) Pub Date : 2024-02-21 Robert Ross, Ross Arena, Jonathan Myers, Peter Kokkinos, Leonard A. Kaminsky
-
Real-world experience with mavacamten in obstructive hypertrophic cardiomyopathy: Observations from a tertiary care center Prog. Cardiovasc. Dis. (IF 9.1) Pub Date : 2024-02-13 Milind Y. Desai, Adel Hajj-Ali, Katy Rutkowski, Susan Ospina, Andrew Gaballa, Michael Emery, Craig Asher, Bo Xu, Maran Thamilarasan, Zoran B. Popovic
In symptomatic obstructive hypertrophic cardiomyopathy (oHCM) patients, mavacamten is commercially approved to help improve left ventricular (LV) outflow tract (LVOT) gradients, symptoms, and reduce eligibility for septal reduction therapy (SRT) under the risk evaluation and mitigation strategy (REMS) program. We sought to prospectively report the initial real-world clinical experience with the use
-
New models for heart failure care delivery Prog. Cardiovasc. Dis. (IF 9.1) Pub Date : 2024-02-02 Jeffrey Xia, Nicholas K. Brownell, Gregg C. Fonarow, Boback Ziaeian
Heart failure (HF) is a common disease with increasing prevalence around the world. There is high morbidity and mortality associated with poorly controlled HF along with increasing costs and strain on healthcare systems due to a high rate of rehospitalization and resource utilization. Despite the establishment of clear evidence-based guideline directed medical therapies (GDMT) proven to improve HF
-
2023 update: The importance of cardiorespiratory fitness in the United States Prog. Cardiovasc. Dis. (IF 9.1) Pub Date : 2024-02-02 Leonard A. Kaminsky, Jonathan Myers, Peter H. Brubaker, Barry A. Franklin, Amanda R. Bonikowske, Charles German, Ross Arena
The American Heart Association issued a Policy Statement in 2013 that characterized the importance of cardiorespiratory fitness (CRF) as an essential marker of health outcomes and specifically the need for increased assessment of CRF. This statement summarized the evidence demonstrating that CRF is “.” Subsequently, this Policy Statement led to the development of a National Registry for CRF (Fitness
-
Predicting life expectancy in the United States: The importance of healthy living behaviors and residential geography Prog. Cardiovasc. Dis. (IF 9.1) Pub Date : 2024-02-01 Ross Arena, Nicolaas P. Pronk, Colin Woodard
According to the World Health Organization, 30 countries currently have a life expectancy of ≥80 years: the United States (U.S.) is not among this group of countries. The current analysis assesses the ability of key lifestyle behaviors and characteristics to predict a life expectancy of ≥80 years. Only 577 (19%) of the 3066 U.S. Counties assessed had a life expectancy ≥80 years. These counties had
-
Prioritizing the primary prevention of heart failure: Measuring, modifying and monitoring risk Prog. Cardiovasc. Dis. (IF 9.1) Pub Date : 2024-01-24 Ruchi Patel, Tejasvi Peesay, Vaishnavi Krishnan, Jane Wilcox, Lisa Wilsbacher, Sadiya S. Khan
With the rising incidence of heart failure (HF) and increasing burden of morbidity, mortality, and healthcare expenditures, primary prevention of HF targeting individuals in at-risk HF (Stage A) and pre-HF (Stage B) Stages has become increasingly important with the goal to decrease progression to symptomatic (Stage C) HF. Identification of risk based on traditional risk factors (e.g., cardiovascular
-
Over a decade as editor-in-chief at progress in cardiovascular diseases Prog. Cardiovasc. Dis. (IF 9.1) Pub Date : 2024-01-24 Carl J. Lavie
Abstract not available
-
Estrogen and cardiovascular disease Prog. Cardiovasc. Dis. (IF 9.1) Pub Date : 2024-01-24 Felice Gersh, James H. O'Keefe, Andrew Elagizi, Carl J. Lavie, Jari A. Laukkanen
A large body of scientific research accumulated over the past twenty years documents the cardiovascular (CV) benefits of estradiol (E2) and progesterone (P4) in reproductive aged women. In contrast, accelerated development of CV disease (CVD) occurs in the absence of ovarian produced E2 and P4. Hormone replacement therapy (HRT) with E2 and P4 has been shown to cause no harm to younger menopausal women
-
Advances in the management of heart failure Prog. Cardiovasc. Dis. (IF 9.1) Pub Date : 2024-01-17 Gregg C. Fonarow
Abstract not available
-
RNA in cardiovascular disease: A new frontier of personalized medicine Prog. Cardiovasc. Dis. (IF 9.1) Pub Date : 2024-01-20 Toufik Abdul-Rahman, Ileana Lizano-Jubert, Zarah Sophia Blake Bliss, Neil Garg, Emily Meale, Poulami Roy, Salvatore Antonio Crino, Bethineedi Lakshmi Deepak, Goshen David Miteu, Andrew Awuah Wireko, Abdul Qadeer, Alexandra Condurat, Andra Diana Tanasa, Nikolaos Pyrpyris, Kateryna Sikora, Viktoriia Horbas, Aayushi Sood, Rahul Gupta, Carl J. Lavie
Personalized medicine has witnessed remarkable progress with the emergence of RNA therapy, offering new possibilities for the treatment of various diseases, and in particular in the context of cardiovascular disease (CVD). The ability to target the human genome through RNA manipulation offers great potential not only in the treatment of cardiac pathologies but also in their diagnosis and prevention
-
Advances in the diagnosis and treatment of transthyretin amyloid cardiomyopathy Prog. Cardiovasc. Dis. (IF 9.1) Pub Date : 2024-01-20 Joban Vaishnav, Emily Brown, Kavita Sharma
Transthyretin amyloid cardiomyopathy (ATTR-CM) is an underrecognized cause of heart failure (HF). ATTR-CM can lead to a number of cardiovascular manifestations including HF, rhythm disturbances, and valvular disease that ultimately limit quality of life and prognosis. Due to advances in diagnostic modalities and therapeutic options, the prevalence of ATTR-CM is rising. There are several classes of
-
The economics of heart failure care Prog. Cardiovasc. Dis. (IF 9.1) Pub Date : 2024-01-18 Chen Wei, Paul A. Heidenreich, Alexander T. Sandhu
Heart failure (HF) poses a significant economic burden in the US, with costs projected to reach $70 billion by 2030. Cost-effectiveness analyses play a pivotal role in assessing the economic value of HF therapies. In this review, we overview the cost-effectiveness of HF therapies and discuss ways to improve patient access. Based on current costs, guideline directed medical therapies for HF with reduced
-
Heart failure with improved ejection fraction: Beyond diagnosis to trajectory analysis Prog. Cardiovasc. Dis. (IF 9.1) Pub Date : 2024-01-18 Anthony V. Pensa, Sadiya S. Khan, Ravi V. Shah, Jane E. Wilcox
Left ventricular (LV) systolic dysfunction represents a highly treatable cause of heart failure (HF). A substantial proportion of patients with HF with reduced ejection fraction (EF;HFrEF) demonstrate improvement in LV systolic function (termed HF with improved EF [HFimpEF]), either spontaneously or when treated with guideline-directed medical therapy (GDMT). Although it is a relatively new HF classification
-
Bridging gaps and optimizing implementation of guideline-directed medical therapy for heart failure Prog. Cardiovasc. Dis. (IF 9.1) Pub Date : 2024-01-18 Izza Shahid, Muhammad Shahzeb Khan, Gregg C. Fonarow, Javed Butler, Stephen J. Greene
Despite robust scientific evidence and strong guideline recommendations, there remain significant gaps in initiation and dose titration of guideline-directed medical therapy (GDMT) for heart failure (HF) among eligible patients. Reasons surrounding these gaps are multifactorial, and largely attributed to patient, healthcare professionals, and institutional challenges. Concurrently, HF remains a predominant
-
Modern advances in heart transplantation Prog. Cardiovasc. Dis. (IF 9.1) Pub Date : 2024-01-18 Pratyaksh K. Srivastava, Michelle M. Kittleson
Heart transplantation (HTx) is the only definitive therapy for patients with end stage heart disease. With the increasing global prevalence of heart failure, the demand for HTx has continued to grow and outpace supply. In this paper, we will review advances in the field of HTx along the clinical journey of a HTx recipient. Starting with the sensitized patient, we discuss current methods to define sensitization
-
Emerging devices for heart failure management Prog. Cardiovasc. Dis. (IF 9.1) Pub Date : 2024-01-18 Fouad Chouairi, Allison Levin, Jan Biegus, Marat Fudim
There have been significant advances in the treatment of heart failure (HF) in recent years, driven by significant strides in guideline-directed medical therapy (GDMT). Despite this, HF is still associated with high levels of morbidity and mortality, and most patients do not receive optimal medical therapy. In conjunction with the improvement of GDMT, novel device therapies have been developed to better
-
The spectrum of post-myocardial infarction care: From acute ischemia to heart failure Prog. Cardiovasc. Dis. (IF 9.1) Pub Date : 2024-01-17 Khawaja Hassan Akhtar, Muhammad Shahzeb Khan, Suzanne J. Baron, Shelley Zieroth, Jerry Estep, Daniel Burkhoff, Javed Butler, Marat Fudim
Heart failure (HF) is the leading cause of mortality in patients with acute myocardial infarction (AMI), with incidence ranging from 14% to 36% in patients admitted due to AMI. HF post-MI develops due to complex inter-play between macrovascular obstruction, microvascular dysfunction, myocardial stunning and remodeling, inflammation, and neuro-hormonal activation. Cardiogenic shock is an extreme presentation
-
Evolution of Mechanical Circulatory Support for advanced heart failure Prog. Cardiovasc. Dis. (IF 9.1) Pub Date : 2024-01-17 Cathrine M. Moeller, Andrea Fernandez Valledor, Daniel Oren, Gal Rubinstein, Gabriel T. Sayer, Nir Uriel
This comprehensive review highlights the significant advancements in Left Ventricular Assist Device (LVAD) therapy, emphasizing its evolution from the early pulsatile flow systems to the cutting-edge continuous-flow devices, particularly the HeartMate 3 (HM3) LVAD. These advancements have notably improved survival rates, reduced complications, and enhanced the quality of life (QoL) for patients with
-
The weekly mortality for ischemic heart disease in the US still peaks on mondays Prog. Cardiovasc. Dis. (IF 9.1) Pub Date : 2024-01-12 Giuseppe Lippi, Camilla Mattiuzzi, Fabian Sanchis-Gomar
Abstract not available
-
The current state of evidence for sodium and fluid restriction in heart failure Prog. Cardiovasc. Dis. (IF 9.1) Pub Date : 2024-01-11 Eloisa Colin-Ramirez, Joanne Arcand, Clara Saldarriaga, Justin A. Ezekowitz
The field of heart failure has evolved in terms of the therapies that are available including pharmaceutical and device therapies. There is now substantial randomized trial data to indicate that dietary sodium restriction does not provide the reduction in clinical events with accepted heterogeneity in the clinical trial results. Dietary sodium restriction should be considered for some but not all patients
-
Health equity in heart failure Prog. Cardiovasc. Dis. (IF 9.1) Pub Date : 2024-01-10 Aishwarya Vijay, Clyde W. Yancy
The treatment of heart failure (HF) with reduced ejection fraction (HFrEF) has substantially developed over the past decades. More than ever before, the application of appropriate evidence-based medical therapy for HFrEF is associated with remarkable improvements in survival, noteworthy increases in quality of life, and a marked reduction in symptomatic HF sufficient to warrant hospitalization. These
-
Update on obesity, the obesity paradox, and obesity management in heart failure Prog. Cardiovasc. Dis. (IF 9.1) Pub Date : 2024-01-09 Pamela L. Alebna, Anurag Mehta, Amin Yehya, Adrian da Silva-de Abreu, Carl J. Lavie, Salvatore Carbone
Obesity is a major public health challenge worldwide. It is costly, predisposes to many cardiovascular (CV) diseases (CVD), is increasing at an alarming rate, and disproportionately affects people of low-socioeconomic status. It has a myriad of deleterious effects on the body, particularly on the CV system. Obesity is a major risk factor for heart failure (HF) and highly prevalent in this population
-
Role of exercise therapy and cardiac rehabilitation in heart failure Prog. Cardiovasc. Dis. (IF 9.1) Pub Date : 2024-01-09 Lajjaben Patel, Ritika Dhruve, Neil Keshvani, Ambarish Pandey
Heart failure (HF) is a common cause of hospitalization and death, and the hallmark symptoms of HF, including dyspnea, fatigue, and exercise intolerance, contribute to poor patient quality of life (QoL). Cardiac rehabilitation (CR) is a comprehensive disease management program incorporating exercise training, cardiovascular risk factor management, and psychosocial support. CR has been demonstrated
-
Long-term continuous exercise training counteracts the negative impact of the menopause transition on cardiometabolic health in hypertensive women - a 9-year RCT follow-up Prog. Cardiovasc. Dis. (IF 9.1) Pub Date : 2023-12-07 Magni Mohr, Tórur Sjúrðarson, May-Britt Skoradal, Nikolai B. Nordsborg, Peter Krustrup
Purpose The study examined effects of 9-yrs of multicomponent exercise training during the menopause interval on cardiometabolic health in hypertensive women. Methods Sedentary, middle-aged women (n = 25) with mild-to-moderate arterial hypertension were randomized into a soccer training (multicomponent exercise; EX; n = 12) or control group (CON; n = 13). EX took part in 1-h football training sessions
-
The link between impaired oxygen supply and cognitive decline in peripheral artery disease Prog. Cardiovasc. Dis. (IF 9.1) Pub Date : 2023-12-06 Johannes Burtscher, Grégoire P. Millet, Marco Fresa, Stefano Lanzi, Lucia Mazzolai, Maxime Pellegrin
Although peripheral artery disease (PAD) primarily affects large arteries outside the brain, PAD is also associated with elevated cerebral vulnerabilities, including greater risks for brain injury (such as stroke), cognitive decline and dementia. In the present review, we aim to evaluate recent literature and extract information on potential mechanisms linking PAD and consequences on the brain. Furthermore
-
-
-
-
-
Subclinical atherosclerosis on chest computed tomography and mortality in young patients with severe hypercholesterolemia Prog. Cardiovasc. Dis. (IF 9.1) Pub Date : 2023-11-04 Pamela Piña, Carol Fernandez, Daniel Lorenzatti, Francesco Castagna, Jeremy Miles, Toshiki Kuno, Andrea Scotti, Javier Arce, Carlos A. Gongora, Aldo L. Schenone, Matthew J. Budoff, Khurram Nasir, Ron Blankstein, Michael J. Blaha, Damini Dey, Daniel S. Berman, Jeffrey M. Levsky, Salim S. Virani, Mario J. Garcia, Leandro Slipczuk
Abstract not available
-
Introduction to assorted topics II 2023 Prog. Cardiovasc. Dis. (IF 9.1) Pub Date : 2023-11-03 Carl J. Lavie
Abstract not available
-
Transcatheter edge-to-edge repair in mitral regurgitation: A comparison of device systems and recommendations for tailored device selection. A systematic review and meta-analysis Prog. Cardiovasc. Dis. (IF 9.1) Pub Date : 2023-11-02 Basel F. Alqeeq, Mohammed Al-Tawil, Mohammed Hamam, Mohammad Aboabdo, Mohammed I. Elrayes, Juergen Leick, Mohamed Zeinah, Assad Haneya, Amer Harky
-
Role of multimodality imaging in infective endocarditis: Contemporary diagnostic and prognostic considerations Prog. Cardiovasc. Dis. (IF 9.1) Pub Date : 2023-10-30 Bo Xu, Krishna O. Sanaka, Ikram-Ul Haq, Reza M. Reyaldeen, Duygu Kocyigit, Gösta B. Pettersson, Shinya Unai, Paul Cremer, Richard A. Grimm, Brian P. Griffin
-
Comparison of coronary artery calcium scores among patients referred for cardiac imaging tests Prog. Cardiovasc. Dis. (IF 9.1) Pub Date : 2023-10-17 Alan Rozanski, Donghee Han, Robert J.H. Miller, Heidi Gransar, Piotr Slomka, Sean W. Hayes, John D. Friedman, Louise E.J. Thomson, Daniel S. Berman
Background While coronary artery calcium (CAC) can now be evaluated by multiple imaging modalities, there is presently scant study regarding how CAC scores may vary among populations of varying clinical risk. Methods We evaluated the distribution of CAC scores among three patient groups: 18,941 referred for CAC scanning, 5101 referred for diagnostic coronary CT angiography (CCTA), and 3307 referred
-
SGLT inhibitors for improving Healthspan and lifespan Prog. Cardiovasc. Dis. (IF 9.1) Pub Date : 2023-10-17 James H. O'Keefe, Robert Weidling, Evan L. O'Keefe, W. Grant Franco
Sodium-glucose cotransporter inhibitor/inhibition (SGLTi), initially approved as a glucose-lowering therapy for type 2 diabetes, is associated with decreased risks for many of the most common conditions of aging, including heart failure, chronic kidney disease, all-cause hospitalization, atrial fibrillation, cancer, gout, emphysema, neurodegenerative disease/dementia, emphysema, non-alcoholic fatty
-
Higher diet quality relates to better cardiac function in cancer survivors: The multi-ethnic study of atherosclerosis Prog. Cardiovasc. Dis. (IF 9.1) Pub Date : 2023-10-16 Moriah P. Bellissimo, Salvatore Carbone, Jian He, Jennifer H. Jordan, Bharath Ambale-Venkatesh, Joao A. Lima, Jessica Gokee LaRose, Fadi N. Salloum, Dipankar Bandyopadhyay, W. Gregory Hundley
Background Cancer therapies induce cardiac injury and increase cardiovascular disease (CVD) risk. In non-cancer populations, higher diet quality is associated with protection against CVD, but the relationship between diet and cardiac function in cancer survivors is unknown. Methods This cross-sectional analysis from the Multi-Ethnic Study of Atherosclerosis (MESA) cohort included 113 cancer survivors
-
Characteristics of patients with recurrent acute myocardial infarction after MINOCA Prog. Cardiovasc. Dis. (IF 9.1) Pub Date : 2023-10-16 Giuseppe Ciliberti, Federico Guerra, Carmine Pizzi, Marco Merlo, Filippo Zilio, Francesco Bianco, Massimo Mancone, Denise Zaffalon, Rocco Gioscia, Luca Bergamaschi, Paolo Compagnucci, Matteo Armillotta, Michela Casella, Angelo Sansonetti, Marco Marini, Pasquale Paolisso, Giulia Stronati, Sabina Gallina, Antonio Dello Russo, Gian Piero Perna, Monica Verdoia
Background Myocardial infarction (MI) with non-obstructed coronary arteries (MINOCA) is an increasingly recognized condition with challenging management. Some MINOCA patients ultimately experience recurrent acute MI (re-AMI) during follow-up; however, clinical and angiographic factors predisposing to re-AMI are still poorly defined. Methods In this retrospective multicenter cohort study we enrolled
-
Assessing the potential of ChatGPT for patient education in the cardiology clinic Prog. Cardiovasc. Dis. (IF 9.1) Pub Date : 2023-10-11 Chayakrit Krittanawong, Mario Rodriguez, Scott Kaplin, W.H. Wilson Tang
Abstract not available
-
Outcomes of untreated subclinical antibody-mediated rejection after heart transplantation Prog. Cardiovasc. Dis. (IF 9.1) Pub Date : 2023-10-10 Jacinthe Boulet, Jane Kelleher, Mauro R.B. Wanderley, Anju Nohria, Charlotte Andersson, Miae Kim, Mandeep R. Mehra
Subclinical antibody-mediated rejection (AMR) is represented by histopathological and/or immunopathological manifestations in the absence of significant cardiac allograft dysfunction. Treatment remains uncertain as there is a lack of data on asymptomatic heart transplant (HT) recipients (HTR) with a positive cardiac biopsy. We sought to determine the impact of untreated subclinical biopsy-proven AMR
-
Self-reported walking pace and 10-year cause-specific mortality: A UK biobank investigation Prog. Cardiovasc. Dis. (IF 9.1) Pub Date : 2023-09-30 Jonathan Goldney, Paddy C. Dempsey, Joseph Henson, Alex Rowlands, Atanu Bhattacharjee, Yogini V. Chudasama, Cameron Razieh, Jari A. Laukkanen, Melanie J. Davies, Kamlesh Khunti, Thomas Yates, Francesco Zaccardi
Objective To investigate associations of self-reported walking pace (SRWP) with relative and absolute risks of cause-specific mortality. Patients and methods In 391,652 UK Biobank participants recruited in 2006–2010, we estimated sex- and cause-specific (cardiovascular disease [CVD], cancer, other causes) mortality hazard ratios (HRs) and 10-year mortality risks across categories of SRWP (slow, average
-
-
-
-
-
-
-